Last edition
News about "Mike Doustdar"
Novo Nordisk Seeks FDA Approval for CagriSema Weight-Loss Therapy
CagriSema 2.4 mg/2.4 mg is an investigational once-weekly injectable combining cagrilintide and semaglutide to target complementary obesity pathways. In the REDEFINE 1 phase III trial, patients with obesity or overweight achieved an average weight loss of 23 percent, reinforcing the company’s ongoing focus on innovation in obesity treatment.
Mike Doustdar | 19/12/2025 | By News Bureau
Novo Nordisk to Cut 9,000 Jobs in Global Restructuring Amid Market Pressures
Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss drug Wegovy and diabetes treatment Ozempic, has announced plans to cut 9,000 jobs worldwide—around 11 to 12 per cent of its workforce—as part of a major restructuring programme.
Mike Doustdar | 10/09/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy